It has been reported that STZ-treated mice exhibit hyperglycemia, hyperfiltration, and high urinary albumin levels compared with untreated mice and that these aspects are improved in Sglt2-knockout mice (35) and by SGLT2 inhibitors (36–38). Here, SLC5A2 is linked to Hyperglycemia.